Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

(2016) Yaron Arbel et al.   Cardiovascular Diabetology

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease

(2016) Robert Klempfner et al.  

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease

(2016) Robert Klempfner et al.   Circulation-Cardiovascular Quality and Outcomes

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy

(2015) Carlos Aguiar et al.   ATHEROSCLEROSIS SUPPLEMENTS

Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus

(2015) Marilia C O Sprandel et al.   Cardiovascular Diabetology

Noninvasive study of coronary microcirculation response to a cold pressor test

(2015) Isabelle Pham et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China

(2015) Yidong Wei et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Prevalence of atherogenic dyslipidemia: Association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study

(2014) M. Cabrera et al.   ATHEROSCLEROSIS

Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study

(2014) Maria-Agata Miselli et al.   Cardiovascular Diabetology

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

(2014) Alexander Tenenbaum et al.   Cardiovascular Diabetology

Residual macrovascular risk in 2013: what have we learned?

(2014) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR)

(2014) Katarina Eeg-Olofsson et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High-Risk Patients With Diabetes

(2014) Joseph B. Muhlestein et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography

(2014) Célia Bittencourt et al.   Diabetology & Metabolic Syndrome

LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes

(2013) B Eliasson et al.   European Journal of Preventive Cardiology

Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature

(2011) Paul Valensi et al.   Archives of Cardiovascular Diseases

Triglycerides and Cardiovascular Disease

(2011) Michael Miller et al.   CIRCULATION

Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients

(2011) E. Cosson et al.   DIABETES CARE

Usefulness of the High Triglyceride-to-HDL Cholesterol Ratio to Identify Cardiometabolic Risk Factors and Preclinical Signs of Organ Damage in Outpatient Children

(2011) P. Di Bonito et al.   DIABETES CARE

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study

(2011) L. A. Leiter et al.   DIABETIC MEDICINE

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

(2011) M. John Chapman et al.   EUROPEAN HEART JOURNAL

Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients

(2011) Carmine Gazzaruso et al.   Internal and Emergency Medicine

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

(2010) Vincent J. Carey et al.   AMERICAN JOURNAL OF CARDIOLOGY

Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i)

(2010) J.C. Fruchart et al.   CURRENT MEDICAL RESEARCH AND OPINION

Lipids, lipid-lowering therapy and diabetes complications

(2010) P. Valensi et al.   DIABETES & METABOLISM

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2009) D. C. Burgess et al.   EUROPEAN HEART JOURNAL

Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes

(2009) Lawrence H. Young et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION